Literature DB >> 26556815

Successes of SPRINT, but Still Some Hurdles to Cross.

Rhian M Touyz1, Anna F Dominiczak2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26556815     DOI： 10.1161/HYPERTENSIONAHA.115.06725

Source DB:  PubMed          Journal:  Hypertension        ISSN： 0194-911X            Impact factor:   10.190


× No keyword cloud information.
  7 in total

Review 1.  Going Beyond the Guidelines in Individualising the Use of Antihypertensive Drugs in Older Patients.

Authors:  Ian A Scott; Sarah N Hilmer; David G Le Couteur
Journal:  Drugs Aging       Date:  2019-08       Impact factor: 3.923

2.  Hypertension Across the Atlantic: A Sprint or a Marathon?

Authors:  Massimo Volpe; Barbara Citoni; Roberta Coluccia; Allegra Battistoni; Giuliano Tocci
Journal:  High Blood Press Cardiovasc Prev       Date:  2017-04-27

3.  Hypertension Treatment ACCORDing to SPRINT.

Authors:  Karla Campos; Samar Sheth; Stephanie A Coulter
Journal:  Tex Heart Inst J       Date:  2016-08-01

Review 4.  Blood pressure reduction in diabetes: lessons from ACCORD, SPRINT and EMPA-REG OUTCOME.

Authors:  Pantelis A Sarafidis; Antonios A Lazaridis; Gema Ruiz-Hurtado; Luis M Ruilope
Journal:  Nat Rev Endocrinol       Date:  2017-01-20       Impact factor: 43.330

Review 5.  BP Targets in Hypertension: What Should We Do Now That SPRINT Is Out?

Authors:  Hemal Bhatt; Lama Ghazi; David Calhoun; Suzanne Oparil
Journal:  Curr Cardiol Rep       Date:  2016-10       Impact factor: 2.931

Review 6.  The optimal blood pressure target in diabetes mellitus: a quest coming to an end?

Authors:  Eirini Papadopoulou; Elena Angeloudi; Spiridon Karras; Pantelis Sarafidis
Journal:  J Hum Hypertens       Date:  2018-06-22       Impact factor: 3.012

7.  Incremental effects of antihypertensive drugs: instrumental variable analysis.

Authors:  Adam A Markovitz; Jacob A Mack; Brahmajee K Nallamothu; John Z Ayanian; Andrew M Ryan
Journal:  BMJ       Date:  2017-12-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.